Replies to post #1005 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Interesting discussion re the regulatory process vis. GTCB's platform.<

It is indeed. The broader subject of biosimilar drugs will be one of great importance for drug/biotech investors during the next decade, when patents will expire on several big-selling biotech drugs. Meanwhile, there will be political pressure to establish a regulatory process that facilitates the approval of cheaper knockoff versions of these very expensive drugs.

Nevertheless, it’s a mistake for investors to assume that these changes will occur in time to benefit GTC in the programs is it currently considering such as rhFViia and rhAAT. Dr. Cox said as much on the latest CC and he could not possibly have been any clearer.